Production (Stage)
Arrowhead Pharmaceuticals, Inc.
ARWR
$15.13
-$0.26-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -29.60% | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -29.60% | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -29.60% | -100.00% | -- | -- |
| SG&A Expenses | 13.40% | 12.16% | 11.37% | 7.91% | 19.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.99% | 17.00% | 30.36% | 48.61% | 28.63% |
| Operating Income | 402.08% | -18.21% | -49.73% | -71.51% | -362.00% |
| Income Before Tax | 391.05% | -26.26% | -58.54% | -68.28% | -366.37% |
| Income Tax Expenses | -- | 103.11% | -73.04% | -- | -- |
| Earnings from Continuing Operations | 389.67% | -29.43% | -56.14% | -67.08% | -366.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 52.24% | -15.09% | 110.18% | 170.06% | 69.77% |
| Net Income | 395.65% | -30.27% | -55.49% | -65.91% | -357.42% |
| EBIT | 402.08% | -18.21% | -49.73% | -71.51% | -362.00% |
| EBITDA | 418.32% | -18.06% | -50.45% | -72.35% | -339.34% |
| EPS Basic | 373.31% | -12.09% | -34.06% | -42.94% | -322.92% |
| Normalized Basic EPS | 377.99% | -9.70% | -35.80% | -43.37% | -318.41% |
| EPS Diluted | 369.61% | -12.10% | -34.06% | -43.44% | -326.67% |
| Normalized Diluted EPS | 375.67% | -9.70% | -35.80% | -43.37% | -321.24% |
| Average Basic Shares Outstanding | 8.17% | 16.23% | 15.99% | 16.07% | 15.48% |
| Average Diluted Shares Outstanding | 9.08% | 16.23% | 15.99% | 16.07% | 14.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |